Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Human anti-TNF monoclonal antibody/adalimumab · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Human anti-TNF monoclonal antibody/adalimumab | BIOLOGICAL | - |
Inclusion Criteria: * Subject completed study M02-518 or M02-570 Exclusion Criteria: * Subject prematurely discontinued study M02-518 or M02-570 * Female subject who is pregnant or breast-feeding or considering becoming pregnant * Subject considered by the investigator, for any reason, to be...
Human anti-TNF monoclonal antibody/adalimumab is used for the treatment of psoriatic arthritis. It is a monoclonal antibody being developed for patients with moderate to severely active psoriatic arthritis. The drug is currently in Phase 3 clinical development and is being studied in the United States.
Human anti-TNF monoclonal antibody/adalimumab targets tumor necrosis factor (TNF). As an anti-TNF monoclonal antibody, it is designed to neutralize TNF, a cytokine involved in inflammation. This mechanism is relevant to the treatment of psoriatic arthritis, an inflammatory condition.
Human anti-TNF monoclonal antibody/adalimumab is being developed by Abbott Laboratories, a company traded under the ticker symbol ABT. The drug is currently in Phase 3 clinical development for psoriatic arthritis.
Human anti-TNF monoclonal antibody/adalimumab is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of psoriatic arthritis.
Human anti-TNF monoclonal antibody/adalimumab has one completed Phase 3 clinical trial, identified as NCT00195689. This trial, titled 'Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis,' enrolled 400 participants in the United States. The trial was not randomized, double-blind, or controlled.
Yes, Human anti-TNF monoclonal antibody/adalimumab is the same as adalimumab. The drug is commonly referred to as adalimumab, and it is being developed by Abbott Laboratories for psoriatic arthritis. It is currently in Phase 3 clinical development.